On the public citation graph

Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial

0 signed · 177 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/ijc.27396openalex-snapshot
Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: A meta‐analysis from six phase III randomized controlled trials
inferredcites →https://doi.org/10.1002/ijc.29647openalex-snapshot
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors
inferredcites →https://doi.org/10.1016/j.ejca.2013.06.035openalex-snapshot
Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer
inferredcites →https://doi.org/10.1016/j.ejca.2014.03.007openalex-snapshot
A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer
inferredcites →https://doi.org/10.1016/j.jtho.2016.03.006openalex-snapshot
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR- Activating Mutation
inferredcites →https://doi.org/10.1016/j.lungcan.2011.01.024openalex-snapshot
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed
inferredcites →https://doi.org/10.1016/j.lungcan.2014.07.006openalex-snapshot
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study
inferredcites →https://doi.org/10.1016/j.lungcan.2015.06.002openalex-snapshot
Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation
inferredcites →https://doi.org/10.1016/s0140-6736(08)61758-4openalex-snapshot
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
inferredcites →https://doi.org/10.1016/s1470-2045(09)70364-xopenalex-snapshot
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(11)70393-xopenalex-snapshot
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(13)70254-7openalex-snapshot
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
inferredcites →https://doi.org/10.1021/acs.molpharmaceut.6b00249openalex-snapshot
Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCB1 in Vitro
inferredcites →https://doi.org/10.1056/nejmoa040938openalex-snapshot
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
inferredcites →https://doi.org/10.1056/nejmoa0810699openalex-snapshot
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
inferredcites →https://doi.org/10.1056/nejmoa0909530openalex-snapshot
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
inferredcites →https://doi.org/10.1093/annonc/mdt491openalex-snapshot
A systematic review of the characteristics associated with recall rates, detection rates and positive predictive values of computed tomography screening for lung cancer
inferredcites →https://doi.org/10.1093/annonc/mdw271openalex-snapshot
Chemotherapy remains an essential element of personalized care for persons with lung cancers
inferredcites →https://doi.org/10.1097/jto.0b013e3181e2f624openalex-snapshot
Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era
inferredcites →https://doi.org/10.1097/jto.0b013e3182835577openalex-snapshot
A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1111/ajco.12178openalex-snapshot
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC
inferredcites →https://doi.org/10.1158/0008-5472.can-05-0641openalex-snapshot
Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing ATP-Binding Cassette Family Protein
inferredcites →https://doi.org/10.1158/0008-5472.can-08-0499openalex-snapshot
Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
inferredcites →https://doi.org/10.1158/0008-5472.can-10-0111openalex-snapshot
Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters
inferredcites →https://doi.org/10.1158/1535-7163.mct-07-0567openalex-snapshot
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase
inferredcites →https://doi.org/10.1186/s12885-015-1056-9openalex-snapshot
Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients
inferredcites →https://doi.org/10.1186/s40880-015-0001-2openalex-snapshot
Association of the Asp312Asn and Lys751Gln polymorphisms in the XPD gene with the risk of non-Hodgkin’s lymphoma: evidence from a meta-analysis
inferredcites →https://doi.org/10.1200/jco.2005.02.840openalex-snapshot
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2005.05.1474openalex-snapshot
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
inferredcites →https://doi.org/10.1200/jco.2008.21.5541openalex-snapshot
Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2010.34.4929openalex-snapshot
A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2016.66.9218openalex-snapshot
Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
inferredcites →https://doi.org/10.1371/journal.pone.0048532openalex-snapshot
Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
inferredcites →https://doi.org/10.2147/dddt.s60672openalex-snapshot
The new concepts on overcoming drug resistance in lung cancer
inferredcites →https://doi.org/10.3322/caac.21262openalex-snapshot
Global cancer statistics, 2012
inferredcites →https://doi.org/10.3892/ijo_00000692openalex-snapshot
Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4838305openalex-extracted
First-Third Generation Egfr Inhibitor Combined With Chemotherapy with Advanced Lung Adenocarcinom From A Subgroup Analysis
inferred← citeshttps://doi.org/10.1002/14651858.cd010383.pub2openalex-snapshot
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
inferred← citeshttps://doi.org/10.1002/14651858.cd010383.pub3openalex-snapshot
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
inferred← citeshttps://doi.org/10.1002/cac2.12359openalex-snapshot
Non‐small cell lung cancer in China
inferred← citeshttps://doi.org/10.1002/cam4.3733openalex-snapshot
Cost‐effectiveness analysis of first‐line treatments for advanced epidermal growth factor receptor‐mutant non‐small cell lung cancer patients
inferred← citeshttps://doi.org/10.1002/cpt.3759openalex-snapshot
Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR ‐Mutated Advanced NSCLC
inferred← citeshttps://doi.org/10.1002/ijc.34878openalex-snapshot
Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR‐TKIs
inferred← citeshttps://doi.org/10.1002/jssc.201801165openalex-snapshot
Preparative isolation and purification of steroidal glycoalkaloid from the ripe berries of Solanum nigrum L. by preparative HPLC–MS and UHPLC–TOF‐MS/MS and its anti‐non‐small cell lung tumors effects in vitro and in vivo
inferred← citeshttps://doi.org/10.1002/mco2.105openalex-snapshot
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
inferred← citeshttps://doi.org/10.1002/sim.9810openalex-snapshot
Multi‐state network meta‐analysis of progression and survival data
inferred← citeshttps://doi.org/10.1007/978-3-031-59478-6_16openalex-snapshot
Nanoparticles and Cancer Chemotherapy
inferred← citeshttps://doi.org/10.1007/978-3-031-93894-8_9openalex-snapshot
Receptor Tyrosine Kinase Inhibitors in Combination Therapies: Integrating Chemotherapy and Radiation Therapy for Improved Cancer Treatment
inferred← citeshttps://doi.org/10.1007/s00280-017-3516-1openalex-snapshot
First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
inferred← citeshttps://doi.org/10.1007/s00408-026-00946-3openalex-snapshot
Contemporary Chemotherapy Benchmarks for Molecularly Defined Advanced NSCLC: Reconstructed Individual Patient-Level Data of 22 Randomized Trials
inferred← citeshttps://doi.org/10.1007/s00432-020-03296-6openalex-snapshot
Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments
inferred← citeshttps://doi.org/10.1007/s00432-021-03828-8openalex-snapshot
Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy
inferred← citeshttps://doi.org/10.1007/s11523-019-00649-1openalex-snapshot
Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma
inferred← citeshttps://doi.org/10.1007/s11523-019-00659-zopenalex-snapshot
Correction to: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR‑Mutant Lung Adenocarcinoma
inferred← citeshttps://doi.org/10.1007/s11523-020-00708-yopenalex-snapshot
Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study
inferred← citeshttps://doi.org/10.1016/j.bbcan.2021.188645openalex-snapshot
Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.bbrc.2023.149344openalex-snapshot
Characterization and verification of CD81 as a potential target in lung squamous cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.cej.2019.122541openalex-snapshot
Co-delivery of erlotinib and doxorubicin by MoS2 nanosheets for synergetic photothermal chemotherapy of cancer
inferred← citeshttps://doi.org/10.1016/j.clinsp.2022.100152openalex-snapshot
Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis
inferred← citeshttps://doi.org/10.1016/j.clinthera.2019.12.006openalex-snapshot
Front-line Therapy in Advanced Non–Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis
inferred← citeshttps://doi.org/10.1016/j.cllc.2020.06.005openalex-snapshot
EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study
inferred← citeshttps://doi.org/10.1016/j.cllc.2024.02.005openalex-snapshot
QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review
inferred← citeshttps://doi.org/10.1016/j.cllc.2024.06.002openalex-snapshot
The Design for a Phase II, Randomized, Multicenter Study of CtDNA-Guided Treatment With Furmonertinib Combined Therapy or Furmonertinib Alone for Untreated Advanced EGFR Mutant Non–small-cell Lung Cancer Patients: The FOCUS-C Study
inferred← citeshttps://doi.org/10.1016/j.clon.2025.103776openalex-snapshot
Comparing the Effectiveness and Safety of First-line Interventions in Patients With Advanced Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer, With Particular Focus on Brain Metastatic Status: A Systematic Review and Network Meta-analysis
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2019.102820openalex-snapshot
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2021.103225openalex-snapshot
Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2021.103305openalex-snapshot
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2021.103393openalex-snapshot
Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2021.103454openalex-snapshot
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2022.103760openalex-snapshot
Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis
inferred← citeshttps://doi.org/10.1016/j.esmoop.2021.100271openalex-snapshot
Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study
inferred← citeshttps://doi.org/10.1016/j.esmoop.2021.100347openalex-snapshot
Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.intimp.2020.106477openalex-snapshot
Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures
inferred← citeshttps://doi.org/10.1016/j.jtho.2024.04.009openalex-snapshot
“Tumor-free survival” Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC
inferred← citeshttps://doi.org/10.1016/j.jtocrr.2022.100322openalex-snapshot
Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis
inferred← citeshttps://doi.org/10.1016/j.lungcan.2019.05.008openalex-snapshot
Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study
inferred← citeshttps://doi.org/10.1016/j.lungcan.2019.07.024openalex-snapshot
Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients
inferred← citeshttps://doi.org/10.1016/j.lungcan.2025.108676openalex-snapshot
Icotinib plus chemotherapy as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutant lung adenocarcinoma: a phase II study (NEOIPOWER)
inferred← citeshttps://doi.org/10.1016/j.vhri.2023.08.006openalex-snapshot
Cost-Effectiveness of Comprehensive Genomic Profiling in Patients With Non–Small Cell Lung Cancer for the Colombian Health System
inferred← citeshttps://doi.org/10.1016/s1877-1203(16)30126-4openalex-snapshot
Les cancers bronchiques non à petites cellules EGFR-mutés
inferred← citeshttps://doi.org/10.1016/s1877-1203(17)30054-xopenalex-snapshot
Les cancers bronchiques non à petites cellules EGFR-mutés
inferred← citeshttps://doi.org/10.1021/acsomega.2c03270openalex-snapshot
Gefitinib Inhibits Rifampicin-Induced CYP3A4 Gene Expression in Human Hepatocytes
inferred← citeshttps://doi.org/10.1039/d4ce00039kopenalex-snapshot
Gefitinib salts/cocrystals with phenolic acids as a promising solid-state approach to improve solubility
inferred← citeshttps://doi.org/10.1056/nejmoa2306434openalex-snapshot
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
inferred← citeshttps://doi.org/10.1056/nejmoa2510308openalex-snapshot
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
inferred← citeshttps://doi.org/10.1080/14656566.2021.1888928openalex-snapshot
An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update
inferred← citeshttps://doi.org/10.1080/14656566.2021.1957096openalex-snapshot
The treatment of advanced lung adenocarcinoma with activating EGFR mutations
inferred← citeshttps://doi.org/10.1080/14656566.2025.2464903openalex-snapshot
Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer
inferred← citeshttps://doi.org/10.1080/14728214.2018.1558203openalex-snapshot
Emerging drugs for EGFR-mutated non-small cell lung cancer
inferred← citeshttps://doi.org/10.1080/14737140.2024.2362889openalex-snapshot
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials
inferred← citeshttps://doi.org/10.1097/cm9.0000000000002468openalex-snapshot
Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis
inferred← citeshttps://doi.org/10.1097/cm9.0000000000004016openalex-snapshot
Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997–2026)
inferred← citeshttps://doi.org/10.1097/coc.0000000000001138openalex-snapshot
Meta-analysis of Targeted Therapies in EGFR-mutated Non–Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1097/md.0000000000034110openalex-snapshot
Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
inferred← citeshttps://doi.org/10.1101/2022.06.11.22276127openalex-snapshot
A systematic review and meta-analysis on effectiveness and safety of traditional Chinese medicine combined with EGFR-TKIs in treating advanced non-small cell lung cancer
inferred← citeshttps://doi.org/10.1111/1759-7714.13679openalex-snapshot
Real‐life effectiveness of first‐line anticancer treatments in stage IIIB / IV NSCLC patients: Data from the C zech TULUNG R egistry
inferred← citeshttps://doi.org/10.1111/1759-7714.14057openalex-snapshot
Concurrent chemotherapy and first‐generation epidermal growth factor receptor ( EGFR )‐tyrosine kinase inhibitors ( TKIs ) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation
inferred← citeshttps://doi.org/10.1111/1759-7714.14783openalex-snapshot
Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR‐TKIs in advanced non‐small cell lung cancer: A systematic review and network meta‐analysis
inferred← citeshttps://doi.org/10.1111/cts.12951openalex-snapshot
Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
inferred← citeshttps://doi.org/10.1136/bmj.l5460openalex-snapshot
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis
inferred← citeshttps://doi.org/10.1155/2021/9311875openalex-snapshot
Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis
inferred← citeshttps://doi.org/10.1155/2023/3335959openalex-snapshot
LncRNA SNHG5 Suppresses Cell Migration and Invasion of Human Lung Adenocarcinoma via Regulation of Epithelial-Mesenchymal Transition
inferred← citeshttps://doi.org/10.1155/2023/5272125openalex-snapshot
The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis
inferred← citeshttps://doi.org/10.11648/j.jctr.20190701.13openalex-snapshot
Gefitinib Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis
inferred← citeshttps://doi.org/10.1177/1758835919891652openalex-snapshot
Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
inferred← citeshttps://doi.org/10.1183/13993003.01100-2018openalex-snapshot
Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer
inferred← citeshttps://doi.org/10.1186/s12885-022-10391-zopenalex-snapshot
Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation
inferred← citeshttps://doi.org/10.1186/s12885-024-13168-8openalex-snapshot
EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
inferred← citeshttps://doi.org/10.1186/s12885-025-15236-zopenalex-snapshot
Assessing first-line treatment for advanced EGFR-mutated NSCLC in diverse clinicopathological subgroups: a systematic review and network meta-analysis
inferred← citeshttps://doi.org/10.1186/s12890-024-03438-3openalex-snapshot
What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis
inferred← citeshttps://doi.org/10.1186/s12916-024-03389-wopenalex-snapshot
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
inferred← citeshttps://doi.org/10.1186/s12935-021-02056-xopenalex-snapshot
SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
inferred← citeshttps://doi.org/10.1186/s13045-019-0731-8openalex-snapshot
Emerging therapies for non-small cell lung cancer
inferred← citeshttps://doi.org/10.1186/s13046-019-1240-xopenalex-snapshot
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
inferred← citeshttps://doi.org/10.1186/s13046-022-02369-3openalex-snapshot
Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence
inferred← citeshttps://doi.org/10.1200/jco.19.01154openalex-snapshot
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR -Mutated Lung Cancer
inferred← citeshttps://doi.org/10.1200/jco.19.03123openalex-snapshot
Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
inferred← citeshttps://doi.org/10.12998/wjcc.v10.i18.6069openalex-snapshot
Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
inferred← citeshttps://doi.org/10.1371/journal.pone.0275919openalex-snapshot
The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials
inferred← citeshttps://doi.org/10.1515/raon-2017-0029openalex-snapshot
Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors
inferred← citeshttps://doi.org/10.18027/2224-5057-2020-10-2-1openalex-snapshot
Meta-analysis of various tki generations efficacy either alone or in combinations in EGFR mutated NSCLC
inferred← citeshttps://doi.org/10.18632/aging.205040openalex-snapshot
A novel risk model of three gefitinib-related genes FBP1, SBK1 and AURKA is related to the immune microenvironment and is predicting prognosis of lung adenocarcinoma patients
inferred← citeshttps://doi.org/10.21037/apm-21-1662openalex-snapshot
Evaluation of safety and efficacy of apatinib combination with chemotherapy for ovarian cancer treatment: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.21037/atm-20-6992openalex-snapshot
Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China
inferred← citeshttps://doi.org/10.21037/tcr-21-653openalex-snapshot
Clinicopathological features of patients with transformation from EGFR mutant lung adenocarcinoma to small cell lung cancer
inferred← citeshttps://doi.org/10.21037/tlcr-22-1openalex-snapshot
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1309922/v1openalex-snapshot
Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1954660/v1openalex-snapshot
First-Third generation EGFR inhibitor combined with cytotoxic chemotherapy in elderly Patients with advanced lung adenocarcinom in routine clinical practice-results from A Subgroup Analysis
inferred← citeshttps://doi.org/10.2147/cmar.s326094openalex-snapshot
Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review
inferred← citeshttps://doi.org/10.2147/dddt.s170678openalex-snapshot
Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.2147/ijn.s372961openalex-snapshot
Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery
inferred← citeshttps://doi.org/10.2147/ott.s157755openalex-snapshot
The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis
inferred← citeshttps://doi.org/10.2147/ott.s332998openalex-snapshot
Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study
inferred← citeshttps://doi.org/10.2174/1574887114666181205155211openalex-snapshot
Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond
inferred← citeshttps://doi.org/10.2217/fon-2019-0270openalex-snapshot
Systematic Review and Network Meta-Analysis of First-Line Therapy for Advanced EGFR -Positive Non-Small-Cell Lung Cancer
inferred← citeshttps://doi.org/10.2217/fon-2020-0651openalex-snapshot
Indirect Analysis of First-Line Therapy for Advanced Non-Small-Cell Lung Cancer with Activating Mutations in a Japanese Population
inferred← citeshttps://doi.org/10.2217/fon-2021-0885openalex-snapshot
Efficacy and Safety of First-Line Therapies in EGFR -Mutated Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis
inferred← citeshttps://doi.org/10.22541/au.169539856.67793836/v1openalex-snapshot
Real-Life Use of First-Generation EGFR-TKI with Chemotherapy in EGFR-sensitive Mutations in Non-Small-Cell Lung Cancer: A Single-Center Analysis and Meta-Analysis
inferred← citeshttps://doi.org/10.33540/487openalex-snapshot
Real-world treatment outcomes in metastatic lung cancer
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1393404openalex-snapshot
Efficacy and safety of a novel TKI (anlotinib) for the treatment of advanced digestive system neoplasms: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3389/fonc.2021.598265openalex-snapshot
First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.3389/fonc.2022.616546openalex-snapshot
An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer
inferred← citeshttps://doi.org/10.3389/fphar.2022.862640openalex-snapshot
The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China
inferred← citeshttps://doi.org/10.3389/fphar.2023.1259221openalex-snapshot
Case report: Clinical management of recurrent small cell lung cancer transformation complicated with lung cancer-induced acute pancreatitis after lung adenocarcinoma surgery
inferred← citeshttps://doi.org/10.3389/fphar.2025.1503171openalex-snapshot
Addition of bevacizumab to gefitinib plus chemotherapy as first-line therapy in EGFR L858R mutate advanced non-small cell lung cancer patients
inferred← citeshttps://doi.org/10.3389/fphar.2025.1519849openalex-snapshot
Adverse event profiles of EGFR-TKI: network meta-analysis and disproportionality analysis of the FAERS database
inferred← citeshttps://doi.org/10.3389/fphar.2025.1586332openalex-snapshot
Comparative analysis of first-generation epidermal growth factor receptor inhibitors combined with chemotherapy versus third-generation epidermal growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3389/fpubh.2021.677862openalex-snapshot
Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone
inferred← citeshttps://doi.org/10.3390/cancers14143362openalex-snapshot
Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis
inferred← citeshttps://doi.org/10.3390/cancers14194894openalex-snapshot
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced EGFR-Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis
inferred← citeshttps://doi.org/10.3390/cancers17050847openalex-snapshot
New Treatment Strategies in Advanced Epidermal Growth Factor Receptor-Driven Non-Small Cell Lung Cancer: Beyond Single Agent Osimertinib
inferred← citeshttps://doi.org/10.3390/curroncol29110636openalex-snapshot
Advanced Lung Cancer Patients’ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada
inferred← citeshttps://doi.org/10.3390/ph13100273openalex-snapshot
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
inferred← citeshttps://doi.org/10.3390/targets2030014openalex-snapshot
Novel Combination of Therapeutic Approaches in Advanced NSCLC with EGFR Activating Mutations
inferred← citeshttps://doi.org/10.37469/0507-3758-2021-67-2-246-253openalex-snapshot
Efficiency integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer and an activating EGFR gene mutation.
inferred← citeshttps://doi.org/10.3892/ol.2021.12781openalex-snapshot
Potential of the cell‑free blood‑based biomarker uroplakin 2 RNA to detect recurrence after surgical resection of lung adenocarcinoma
inferred← citeshttps://doi.org/10.3892/ol.2022.13482openalex-snapshot
Age does matter in adolescents and young adults vs. older adults with lung adenocarcinoma: A retrospective analysis comparing clinical characteristics and outcomes in response to systematic treatments
inferred← citeshttps://doi.org/10.3892/ol.2024.14855openalex-snapshot
Patients with non‑small cell lung cancer with the exon 21 L858R mutation: From distinct mechanisms to epidermal growth factor receptor tyrosine kinase inhibitor treatments (Review)
inferred← citeshttps://doi.org/10.3892/or.2018.6499openalex-snapshot
A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation
inferred← citeshttps://doi.org/10.3892/or.2020.7547openalex-snapshot
miR‑10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway
inferred← citeshttps://doi.org/10.4103/jcrt.jcrt_195_20openalex-snapshot
EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations
inferred← citeshttps://doi.org/10.4155/fmc-2022-0007openalex-snapshot
EGFR-Based Dual Inhibitors: Current Status and Perspectives
inferred← citeshttps://doi.org/10.52547/ijrr.19.4.17openalex-snapshot
Observation of efficacy and prognosis of chemoradiotherapy with apatinib in combination with oxaliplatin + 5-fluorouracil + leucovorin in the gastric cancer in advanced stage
inferred← citeshttps://doi.org/10.53011/jmro.2021.01.05openalex-snapshot
A Case Report of EGFR-mutated Metastatic Lung Adenocarcinoma with Long-term Survival on Systemic Treatment
inferred← citeshttps://doi.org/10.58489/2836-6387/002openalex-snapshot
First-Third generation EGFR inhibitor combined with cytotoxic chemotherapy in elderly Patients with advanced lung adenocarcinom in routine clinical practice-results from A Subgroup Analysis
inferred← citeshttps://doi.org/10.6004/jnccn.2019.7383openalex-snapshot
Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel
inferred← citeshttps://doi.org/10.6084/m9.figshare.14906146openalex-snapshot
Additional file 1 of SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
inferred← citeshttps://doi.org/10.6084/m9.figshare.14906149openalex-snapshot
Additional file 2 of SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
inferred← citeshttps://doi.org/10.6084/m9.figshare.14906152openalex-snapshot
Additional file 3 of SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
inferred← citeshttps://doi.org/10.6084/m9.figshare.14906155openalex-snapshot
Additional file 4 of SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
inferred← citeshttps://doi.org/10.6084/m9.figshare.14906158openalex-snapshot
Additional file 5 of SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
inferred← citeshttps://doi.org/10.6084/m9.figshare.19695675openalex-snapshot
Additional file 1 of Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence
inferred← citeshttps://doi.org/10.6084/m9.figshare.25687490openalex-snapshot
Additional file 1 of Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
inferred← citeshttps://doi.org/10.6084/m9.figshare.25687600openalex-snapshot
Additional file 2 of Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
inferred← citeshttps://doi.org/10.6084/m9.figshare.26553026openalex-snapshot
Additional file 1 of Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation
inferred← citeshttps://doi.org/10.62347/ealx9719openalex-snapshot
Ambroxol enhances anti-cancer effect of microtubule-stabilizing drug to lung carcinoma through blocking autophagic flux in lysosome-dependent way: Am J Cancer Res. 2017; 7(12): 2406-2421
inferred← citeshttps://doi.org/10.7150/jca.32205openalex-snapshot
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.